Nicolas A Menzies, Matthew Quaife, Brian W Allwood, Anthony L Byrne, Anna K Coussens, Anthony D Harries, Florian M Marx, Jamilah Meghji, Debora Pedrazzoli, Joshua A Salomon, Sedona Sweeney, Sanne C van Kampen, Robert S Wallis, Rein M G J Houben, Ted Cohen,
The Lancet Global Health,
Volume 9, Issue 12, 2021
Summary: Many individuals who survive tuberculosis disease face ongoing disability and elevated mortality risks. However, the impact of post-tuberculosis sequelae is generally omitted from policy analyses and disease burden estimates. We therefore estimated the global burden of tuberculosis, inclusive of post-tuberculosis morbidity and mortality.
Robert S. Wallis, Sibuse Ginindza, Trevor Beattie, Nishanee Arjun, Morongwe Likoti, Modulakgotla Sebe, Vinodh A. Edward, Mohammed Rassool, Khatija Ahmed, Katherine Fielding, Bintou A. Ahidjo, Mboyo D.T. Vangu, Gavin Churchyard
PLoS ONE 17(2):
e0252097
https://doi.org/10.1371/journal.pone.0252097
Current tuberculosis treatments leave most patients with bronchiectasis and fibrosis, permanent conditions that impair lung function and increase all-cause post-TB mortality. Host-directed therapies (HDTs) may reduce lung inflammation and hasten eradication of infection. Biomarkers can accelerate tuberculosis regimen development, but no studies have yet examined early biomarkers of TB-HDTs
Migliori, G. B., Marx, F. M., Ambrosino, N., Zampogna, E., Schaaf, H. S., van der Zalm, M.M., Allwood, B., Byrne A.L., Mortimer K., Wallis R.S., … Visca, D.
International Journal of Tuberculosis and Lung Disease, 25(10), 797-813
Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the assessment and management of PTLD and the implementation of pulmonary rehabilitation (PR). This is the first consensus-based set of Clinical Standards for PTLD. Our aim is to improve patient care and quality of life by guiding clinicians, programme managers and public health officers in planning and implementing adequate measures to assess and manage PTLD.
Yuling Lin, Alexandra Walker, Marguerite Batta, Sierra Ottilie-Kovelman, Anna Duchenko, Curdin Brugger, Olivia Keiser, Robert S Wallis, Klaus Reither, Fabrizio Tediosi, Marina Antillon.
https://doi.org/10.1136/bmjph-2023-000441
Published: 31 July 2024
Background Chronic obstructive pulmonary disease (COPD) and tuberculosis (TB) impose a substantial economic burden globally. This systematic review summarised the evidence on the costs of COPD, including post-TB diseases in low- and middle-income countries.